Anti-TIF-1γ antibodies can deactivate Smad4 ubiquitination, blocking the TGF-β/Smad signaling pathway, leading to TGF-β resistance in cell proliferation and promoting tumor development. This evidence concerns the gene TRIM33 and neoplasm.